Clinical Trial Update: Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen [Phase 1]

View source ↗

Summary

Phase 1 biodistribution study of CMD-193 in advanced tumours expressing the Lewis-Y antigen; study status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• CMD-193

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2020-08-10